Transplant stories
Real Treatments. Real Families. Real Hope.
Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.
Why Stem Cell Transplants Matter
At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:
- Blood cancers such as leukaemia and lymphoma
- Inherited genetic disorders including thalassemia and sickle cell disease
- Neurological conditions such as cerebral palsy and brain injury
- Immune deficiencies and metabolic disorders
- Emerging therapies for sports injuries, inflammatory conditions, and skin repair
By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.
Proven Track Record
Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.
These samples have helped children and families across the globe face illnesses such as:
- Cerebral Palsy
- Thalassemia
- Leukaemia
- HSV Encephalitis
- Immune system disorders
Each transplant is more than a statistic — it represents a child given new options, and a family given hope.
A Milestone for Families and for Science
Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.
Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.
Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells
As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:
- Families gain access to 1,000,000+ stored cord blood units across the network
- Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
- FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere
Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.
FamiCord Group releases
Patients
7800+
| No. | Source | Source type | Diagnosis | Medical sector | Year of application | Therapy | Country | Age of the recipient |
|---|---|---|---|---|---|---|---|---|
| 301 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Switzerland | 66 |
| 302 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Italy | 63 |
| 303 | Apheresis | Allogeneic | T -Cell Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 45 |
| 304 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Croatia | 57 |
| 305 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 40 |
| 306 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Kazachstan | 8 |
| 307 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 308 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 309 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 68 |
| 310 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 311 | Apheresis | Allogeneic | Diffuse Large B-Cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 63 |
| 312 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 313 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Germany | 44 |
| 314 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 57 |
| 315 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | UK | 62 |
| 316 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2026 | Standard Therapy | Poland | 22 |
| 317 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 72 |
| 318 | Apheresis | allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 68 |
| 319 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Belgium | 63 |
| 320 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Spain | 47 |
| 321 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Poland | 51 |
| 322 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Italy | 70 |
| 323 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Bulgaria | 28 |
| 324 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 68 |
| 325 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 73 |
| 326 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 69 |
| 327 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 10 |
| 328 | Apheresis | Allogeneic | T-cell non-Hodgkin lymphoma / NK | Hematology | 2026 | Standard Therapy | Poland | 19 |
| 329 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2026 | Standard Therapy | Belgium | 48 |
| 330 | Apheresis | Allogeneic | Essential Thrombocythemia | Hematology | 2026 | Standard Therapy | USA | 59 |
| 331 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Ukraine | 58 |
| 332 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 72 |
| 333 | Apheresis | Allogeneic | B-ALL B-cell Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Netherlands | 71 |
| 334 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Poland | 59 |
| 335 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 67 |
| 336 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 67 |
| 337 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 37 |
| 338 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | France | 66 |
| 339 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 48 |
| 340 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 15 |
| 341 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 45 |
| 342 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2026 | Standard Therapy | USA | 61 |
| 343 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 43 |
| 344 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 64 |
| 345 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | USA | 29 |
| 346 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Switzerland | 69 |
| 347 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 61 |
| 348 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 67 |
| 349 | Apheresis | Allogeneic | Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML) | Hematology | 2026 | Standard Therapy | Germany | 36 |
| 350 | Apheresis | Allogeneic | Chronic Myeloid Leukemia | Hematology | 2026 | Standard Therapy | USA | 66 |
| 351 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2026 | Standard Therapy | USA | 66 |
| 352 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 57 |
| 353 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | India | 51 |
| 354 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 25 |
| 355 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 35 |
| 356 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Finland | 40 |
| 357 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2026 | Standard Therapy | USA | 49 |
| 358 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 359 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Italy | 67 |
| 360 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 50 |
| 361 | Apheresis | Allogeneic | T Lymphblastic Leukemia/Lymphoma | Hematology | 2026 | Standard Therapy | Canada | 43 |
| 362 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | France | 74 |
| 363 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Australia | 67 |
| 364 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Germany | 59 |
| 365 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Czechia | 44 |
| 366 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Poland | 56 |
| 367 | Apheresis | Autologous | Anaplastic T Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Portugal | 23 |
| 368 | Apheresis | Autologous | Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 369 | Apheresis | Allogeneic | T-Cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 55 |
| 370 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 371 | Apheresis | Autologous | Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 53 |
| 372 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Spain | 56 |
| 373 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 69 |
| 374 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Lithuania | 60 |
| 375 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 75 |
| 376 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Poland | 58 |
| 377 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 74 |
| 378 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 69 |
| 379 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | USA | 70 |
| 380 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Canada | 25 |
| 381 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Sweden | 65 |
| 382 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Spain | 72 |
| 383 | Apheresis | Allogeneic | Lymphoma Burkitt Histiocytic Sarcoma | Hematology | 2026 | Standard Therapy | Greece | 12 |
| 384 | Apheresis | Allogeneic | Acute Myelogenous Leukaemia | Hematology | 2026 | Standard Therapy | France | 69 |
| 385 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2026 | Standard Therapy | USA | 69 |
| 386 | Apheresis | Allogeneic | Acute Myeloid Leukemia FLT3-ITD positive | Hematology | 2026 | Standard Therapy | Romania | 11 |
| 387 | Apheresis | Allogeneic | Myelofibrosis (MF) | Hematology | 2026 | Standard Therapy | Lithuania | 67 |
| 388 | Apheresis | Allogeneic | X-ALD (E 71.3) | Hematology | 2026 | Standard Therapy | Czechia | 5 |
| 389 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 73 |
| 390 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 36 |
| 391 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Netherlands | 56 |
| 392 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 53 |
| 393 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Ukraine | 39 |
| 394 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 24 |
| 395 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 62 |
| 396 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 70 |
| 397 | Apheresis | Allogeneic | Other Malignancy | Hematology | 2026 | Standard Therapy | USA | 71 |
| 398 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 62 |
| 399 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 59 |
| 400 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 70 |
Stem cell transplantation has become an established procedure
700,000
cord blood collections have been undertaken globally
50,000
hematopoietic stem cell transplants take place every year
400/500
of these transplants are in Europe
Smart Cells releases
UK samples released
24
| Sample release date | Medical condition | Recipient relationship | Age of the recipient | Unit volume | Medical center | Country |
|---|---|---|---|---|---|---|
| 2005.11 | Thalassemia | Allogeneic (Sibling) | 4 Years | 144ml | Mount Vernon Hospital | Singapore |
| 2005.11 | Leukaemia | Allogeneic (Sibling) | Restricted | Restricted | Stem Cells and Immunology Department, Birmingham | UK |
| 2007.02 | Thalassemia | Allogeneic (Sibling) | 7 Years | 76ml | Kinderlink der Tu Munchen | Germany |
| 2009.08 | Cerebral Palsy | Autologous (Self) | 3 Years | 51ml | Duke University, North Carolina | USA |
| 2010.01 | Cerebral Palsy | Autologous (Self) | 3 Years | 81ml | Duke University, North Carolina | USA |
| 2013.10 | Thalassemia | Allogeneic (Sibling) | 5 Years | 58ml | Catherine Lewis Centre, Hammersmith | UK |
| 2014.01 | Leukaemia | Allogeneic (Sibling) | 4 Years | 71ml | Medizinische Hochschule, Hanover | Germany |
| 2014.05 | Cerebral Palsy | Autologous (Self) | 1 year | 68ml | Duke University, North Carolina | USA |
| 2014.06 | HSV Encephalitis & NMDA Receptor Antibody Virus | Autologous (Self) | 2 Years | 57ml | Duke University, North Carolina | USA |
| 2014.08 | Hypoxic Ischemic Encephalopathy (HIE) | Autologous (Self) | 3 Months | 39ml | Duke University, North Carolina | USA |
| 2015.02 | Hypoxic Ischemic Encephalopathy (HIE) | Autologous (Self) | 6 Months | 53ml | Duke University, North Carolina | USA |
| 2015.03 | Severe Combined Immune Deficiency | Autologous (Self) | 3 Months | 74ml | Duke University, North Carolina | USA |
| 2015.03 | Sickle Cell Disease | Allogeneic (Sibling) | 2 .5 Years | 57ml | BLK Hospital, New Delhi | India |
| 2015.11 | Thalassemia | Allogeneic (Sibling) | 12 Years | 87ml | Children’s Hospital of Pittsburgh of UPMC | USA |
| 2016.03 | Cerebral Palsy | Allogeneic (Sibling) | 6 Years | 101ml | Duke University, North Carolina | USA |
| 2017.04 | Lymphoblastic Leukaemia (^1) | N/A (Identical twin girls) | Restricted | 125ml | Bambin Gesu Childrens’ Hospital, Rome | Italy |
| 2017.06 | Cerebral Palsy | Autologous (Self) | 7 Years | 82ml | Duke University, North Carolina | USA |
| 2017.06 | Cerebral Palsy | Autologous (Self) | 3.4 Years | 132ml | Duke University, North Carolina | USA |
| 2018.03 | Autism | Autologous (Self) | 5.4 Years | 73ml | Duke University, North Carolina | USA |
| 2018.03 | Cerebral Palsy | Autologous (Self) | 3.4 years | 132ml | Duke University, North Carolina | USA |
| 2019.06 | Cerebral Palsy | Allogeneic (Sibling) | 3 Years | 104ml | Duke University, North Carolina | USA |
| 2022.02 | Cerebral Palsy | Allogeneic (Sibling) | 11 Years | 185ml | Duke University, North Carolina | USA |
| 2023.08 | Cerebral Palsy | Allogeneic (Sibling) | 3 Years | 46ml | Duke University, North Carolina | USA |
| 2024.01 | Thalassaemia | Allogeneic (Sibling) | 8 Years | 45ml | Cincinnati Children’s Hospital Medical Center | USA |